Is Zepbound as Good as Ozempic? A Comprehensive Comparison

Last reviewed: June 22, 2026

Last updated: June 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Both Zepbound (tirzepatide) and Ozempic (semaglutide) activate GLP-1 pathways to reduce appetite and improve blood sugar control, yet they work through fundamentally different mechanisms. Zepbound adds a GIP receptor signal on top of GLP-1 activation, making it a dual-action compound, while Ozempic focuses solely on GLP-1 receptors. Clinical trials show tirzepatide produces greater average weight loss than semaglutide alone, though individual response varies significantly based on genetics and lifestyle factors.

How Tirzepatide and Semaglutide Work Differently

Semaglutide, the active ingredient in Ozempic and Wegovy, binds to GLP-1 receptors in the brain and gut. This single mechanism slows gastric emptying, increases feelings of fullness, and triggers insulin release when blood sugar rises. The drug has been used for diabetes management since 2017 and received FDA approval for weight loss in 2021, making it one of the most studied GLP-1 compounds available.

Tirzepatide, found in Zepbound and Mounjaro, activates both GLP-1 and GIP receptors simultaneously. GIP is an older hormone that regulates energy expenditure and glucose metabolism independently of GLP-1. By targeting two pathways instead of one, tirzepatide creates a more comprehensive metabolic shift. Studies comparing the two compounds show tirzepatide achieves roughly 22% body weight reduction versus 15-17% for semaglutide in head-to-head trials.

Clinical Trial Results: Weight Loss Outcomes Compared

The SUSTAIN and STEP trials established semaglutide's safety and efficacy, with participants losing 10-15 pounds per month during titration phases. Long-term data from the STEP 4 trial showed sustained weight loss over 68 weeks when combined with lifestyle changes. These trials involved thousands of participants and demonstrated consistent results across different populations, though individual outcomes ranged from 5% to 20% total body weight loss.

Tirzepatide's SURPASS trials tested higher doses and found average weight reductions between 20-22% of baseline body weight over 68 weeks. Notably, the highest tirzepatide dose (15 mg weekly) outperformed the maximum semaglutide dose (2.4 mg weekly) in direct efficacy measures. However, both compounds show that genetics play a substantial role—some patients achieve exceptional results while others experience modest benefits, suggesting that genetic variation in GIPR gene expression influences individual drug response.

Side Effects and Tolerability: What to Expect

Both tirzepatide and semaglutide cause similar gastrointestinal side effects, particularly during the dose escalation phase. Nausea, vomiting, constipation, and diarrhea occur in 30-50% of users but typically decrease after the first 4-6 weeks as the body adjusts. Serious adverse events remain uncommon in both drug classes, though both carry black-box warnings for thyroid C-cell tumors in animal models and are contraindicated in patients with personal or family histories of medullary thyroid cancer.

Tirzepatide may produce slightly higher rates of gastrointestinal upset during initial weeks because it introduces dual-pathway stimulation, but long-term tolerability appears comparable to semaglutide. Rare but reported complications include pancreatitis, gallbladder issues, and diabetic retinopathy progression in diabetic patients. Individual tolerance depends heavily on genetic factors affecting how quickly a person's gut and nervous system adapt to GLP-1 and GIP signaling.

Cost and Access: Compounded Options vs Brand Names

Brand-name Zepbound and Ozempic can cost $900-$1,400 monthly without insurance, creating a barrier for many patients seeking weight loss treatment. PlexusDx offers compounded tirzepatide injection at $289/mo month-to-month, or from $249/mo on the 6-month plan and compounded semaglutide injection at $189/mo month-to-month, or from $149/mo on the 6-month plan—both sourced from licensed 503A compounding pharmacies and available across all 50 states without insurance requirements. PlexusDx's pricing remains flat regardless of dose escalation, meaning a patient reaching a higher therapeutic dose pays the same monthly fee as someone beginning treatment.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Ozempic or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Will Zepbound (tirzepatide) make me lose more weight than Ozempic (semaglutide)?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

What does the GIP receptor do that makes tirzepatide different?

GIP (glucose-dependent insulinotropic polypeptide) regulates energy expenditure and how your body uses glucose between meals. By activating both GLP-1 and GIP receptors, tirzepatide creates metabolic effects semaglutide cannot achieve alone, including improved insulin sensitivity and greater appetite suppression. This dual mechanism explains why tirzepatide trials showed stronger weight loss in most participants.

How much less expensive is compounded tirzepatide from PlexusDx compared to brand Zepbound?

PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) versus $900-$1,400 for brand Zepbound without insurance, representing a 60-75% cost reduction. Your dose can increase without any price increase—PlexusDx maintains flat monthly pricing across all dose levels. HSA and FSA accounts cover PlexusDx medications, adding further savings for eligible patients.

Are there serious side effects that differ between tirzepatide and semaglutide?

Both medications carry similar safety profiles, with nausea and constipation being the most common early side effects. Tirzepatide may produce slightly more gastrointestinal discomfort during initial weeks due to dual-pathway activation, but serious complications like pancreatitis and gallbladder issues remain rare in both. Both drugs are contraindicated if you have a personal or family history of medullary thyroid cancer.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Yes—the Precision Peptide Genetic Test identifies your GIPR, FTO, and MC4R variants across 14 metabolic pathways. These genetic markers correlate with how strongly you respond to GLP-1 activation, GIP activation, and overall weight loss trajectory. Testing after your first month of treatment helps PlexusDx personalize your ongoing therapy, whether you stay with your current compound or switch for better results.

Related Reading

• Zepbound Vs Ozempic 2
• Ozempic Vs Zepbound 2
• Ozempic Vs Zepbound
• Zepbound Vs Ozempic

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.